“Multiple Myeloma - Market Insights, Epidemiology and Market Size Forecast-2020” Reports provides an overview of the disease and global market size of the Multiple Myeloma for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Multiple Myeloma from 2010-2020.Multiple myeloma are a type of blood cancer that affects the plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow, crowding out the normal plasma cells that help fight infections.
To Download Sample Report With TOC@ http://www.researchmoz.us/enquiry.php?type=S&repid=655885
These malignant plasma cells then produce abnormal proteins (m protein) which may cause tumors, damage the kidneys, and impair immune system function. In some cases, the malignant cells may cause a single tumor, called a solitary plasmacytoma, but if multiple tumors are formed, then the disease is called multiple myeloma. Multiple myeloma develops in 6.1 per 100,000 people per year. With conventional treatment, median survival is 3–4 years, which may be extended to 5–7 years or longer with advanced treatments. The five year survival rate is 45%.In the United States in 2014, there will be an estimated 24,050 new cases and 11,090 deaths.
Results of a recent study found the incidence of myeloma to be 9.5 cases per 100,000 African Americans and 4.1 cases per 100,000 Caucasian Americans. Among African Americans, myeloma is one of the top 10 leading causes of cancer death. With many possible approaches to study and work through, future strategies will revolve around exploration of the effectiveness of combinations that incorporate new agents in various disease and treatment settings. The use of genetic profiles to further delineate groups for different treatment approaches should enable the introduction of patient-specific treatment programmes in the future.
Scope
Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2010-2020.
It also provides Market size of Multiple Myeloma for United States, EU5 and Japan from 2010 and forecasted Market size to 2020
To Enquire Regarding This Report@ http://www.researchmoz.us/enquiry.php?type=E&repid=655885
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Blog: http://dynamicmarketresearch.blogspot.com/
To Download Sample Report With TOC@ http://www.researchmoz.us/enquiry.php?type=S&repid=655885
These malignant plasma cells then produce abnormal proteins (m protein) which may cause tumors, damage the kidneys, and impair immune system function. In some cases, the malignant cells may cause a single tumor, called a solitary plasmacytoma, but if multiple tumors are formed, then the disease is called multiple myeloma. Multiple myeloma develops in 6.1 per 100,000 people per year. With conventional treatment, median survival is 3–4 years, which may be extended to 5–7 years or longer with advanced treatments. The five year survival rate is 45%.In the United States in 2014, there will be an estimated 24,050 new cases and 11,090 deaths.
Results of a recent study found the incidence of myeloma to be 9.5 cases per 100,000 African Americans and 4.1 cases per 100,000 Caucasian Americans. Among African Americans, myeloma is one of the top 10 leading causes of cancer death. With many possible approaches to study and work through, future strategies will revolve around exploration of the effectiveness of combinations that incorporate new agents in various disease and treatment settings. The use of genetic profiles to further delineate groups for different treatment approaches should enable the introduction of patient-specific treatment programmes in the future.
Scope
Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2010-2020.
It also provides Market size of Multiple Myeloma for United States, EU5 and Japan from 2010 and forecasted Market size to 2020
To Enquire Regarding This Report@ http://www.researchmoz.us/enquiry.php?type=E&repid=655885
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Blog: http://dynamicmarketresearch.blogspot.com/
No comments:
Post a Comment